Current systemic therapies for advanced HCC rely on a combination of multikinase inhibitors (such as sorafenib) or anti-VEGF antibodies/VEGF inhibitors (such as bevacizumab) treatment with immunotherapy (Cappuyns et al., 2024). Here, VEGFA is linked to hepatocellular carcinoma.